We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central ...

The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could ...

With its first-in-class endothelin and angiotensin II receptor antagonist Filspari, Travere Therapeutics is providing a more ...

Amylyx’s recent decision to withdraw its ALS drug Relyvrio from the market highlights an important business decision for ...

The FDA is looking at five big decision deadlines in the coming three weeks, including two for a CAR-T therapy and another ...

While these technologies are now a therapeutic reality, the ASGCT 2024 annual meeting this week was a reminder of just how ...

Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine - read this article along with other careers information, tips and ...

With its $525 million investment, Royalty Pharma will acquire the royalties and milestones for ImmuNext’s anti-CD40 therapy ...

Anticipating approval for its COPD therapy ensifentrine, Verona has entered into a $650 million financing deal with Oaktree ...

MacroGenics’ stock dropped by as much as 70% Friday morning after the biotech disclosed five deaths in the Phase II TAMARACK ...

Bluebird bio released its first-quarter 2024 business report on Thursday, touting a nearly 140% year-over-year increase in revenue amid the growing uptake of its three gene therapies. The ...

Overview: In this Q&A, Cell Process Development Scientist at AGC Biologics Cell and Gene Center of Excellence Sara Morlacchi, provides her expert analysis on the current state of the cell therapy ...